Kura Oncology Ownership
| KURA Stock | USD 20.69 0.22 1.07% |
Shares in Circulation | First Issued 2009-06-30 | Previous Quarter 77.3 M | Current Value 83.9 M | Avarage Shares Outstanding 30.5 M | Quarterly Volatility 26.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Kura |
Kura Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The book value of Kura Oncology was now reported as 6.63. The company recorded a loss per share of 2.2. Kura Oncology had not issued any dividends in recent years. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people. To find out more about Kura Oncology contact Troy JD at 858 500 8800 or learn more at https://kuraoncology.com.Kura Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kura Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kura Oncology backward and forwards among themselves. Kura Oncology's institutional investor refers to the entity that pools money to purchase Kura Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2023-12-31 | 1.7 M | Tcg Crossover Management, Llc | 2023-12-31 | 1.4 M | Franklin Resources Inc | 2023-12-31 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.3 M | Paradigm Biocapital Advisors Lp | 2023-12-31 | 1.3 M | Commodore Capital Lp | 2023-12-31 | 1.2 M | Assenagon Asset Management Sa | 2024-03-31 | 1.2 M | Goldman Sachs Group Inc | 2023-12-31 | 1.1 M | Prosight Management, Lp | 2023-12-31 | 950 K | Blackrock Inc | 2023-12-31 | 7.3 M | Suvretta Capital Management, Llc | 2023-12-31 | 6.9 M |
Kura Oncology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kura Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kura Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kura Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dale Stephen over two months ago Disposition of 4825 shares by Dale Stephen of Kura Oncology at 21.5502 subject to Rule 16b-3 | ||
Troy Wilson over three months ago Exercise or conversion by Troy Wilson of 6945 shares of Kura Oncology subject to Rule 16b-3 | ||
Troy Wilson over three months ago Bona fide gift to Troy Wilson of 2000 shares of Kura Oncology subject to Section 16 | ||
Troy Wilson over six months ago Acquisition or disposition of Kura Oncology securities by Troy Wilson | ||
Troy Wilson over a year ago Acquisition or disposition of Kura Oncology securities by Troy Wilson |
Kura Oncology Corporate Filings
8K | 24th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 18th of April 2024 Other Reports | ViewVerify | |
| 12th of April 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.20) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.